Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q54105461)
Watch
English
Ovarian cancer
scholarly article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
title
Ovarian cancer
(English)
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
main subject
ovarian cancer
1 reference
based on heuristic
inferred from title
author
Gordon C. Jayson
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
author name string
Elise C Kohn
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
Henry C Kitchener
series ordinal
3
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
Jonathan A Ledermann
series ordinal
4
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
language of work or name
English
0 references
publication date
21 April 2014
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
volume
384
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
issue
9951
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
page(s)
1376-1388
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
cites work
Recent progress in the diagnosis and treatment of ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Global cancer statistics
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
In vitro fertilization is associated with an increased risk of borderline ovarian tumours
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
ARID1A mutations in endometriosis-associated ovarian carcinomas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prospective study of talc use and ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hereditary gynaecological malignancies: advances in screening and treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Integrated genomic analyses of ovarian carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Frequency of symptoms of ovarian cancer in women presenting to primary care clinics
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifying symptoms of ovarian cancer: a qualitative and quantitative study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Secondary surgical cytoreduction for advanced ovarian carcinoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Second look laparotomy and ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Incorporation of bevacizumab in the primary treatment of ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A phase 3 trial of bevacizumab in ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label tr
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Targeting MET in cancer: rationale and progress
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hormone replacement therapy and survival after surgery for ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Paraneoplastic thrombocytosis in ovarian cancer.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Doctor, does this mean I'm going to starve to death?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Screening for ovarian cancer: a pilot randomised controlled trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of Screening on Ovarian Cancer Mortality
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(13)62146-7
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
Fatcat ID
release_irgpuih6zrfghfkkcqoiwvk3ku
1 reference
stated in
Fatcat
reference URL
https://api.fatcat.wiki/v0/release/irgpuih6zrfghfkkcqoiwvk3ku
retrieved
24 November 2022
based on heuristic
mapped directly with Wikidata item
PubMed ID
24767708
1 reference
stated in
Europe PubMed Central
PubMed ID
24767708
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
